Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease

Why It Matters

Etavopivat could become the first oral treatment to meaningfully reduce crises and boost hemoglobin in sickle cell patients, addressing a major unmet medical need and opening a sizable market for Novo Nordisk.

Key Takeaways

• Etavopivat cut VOC rates by 27% versus placebo.
• Time to first VOC extended to 38.4 weeks, vs 20.9 weeks.
• 48.7% achieved >1 g/dL hemoglobin rise, vs 7.2% placebo.
• Phase III enrolled 385 patients aged 12+ across multiple sites.
• Novo Nordisk targets H2 2026 filing for first‑in‑class oral SCD therapy.

Pulse Analysis

Sickle cell disease (SCD) remains one of the most debilitating hematologic disorders, affecting roughly 100,000 people in the United States alone. Current management relies heavily on intravenous therapies, blood transfusions, and gene‑editing approaches, all of which pose logistical challenges and high costs. An oral agent that can both reduce the frequency of painful vaso‑occlusive crises and improve hemoglobin levels would represent a paradigm shift, offering patients a more convenient, potentially lifelong treatment option.

The HIBISCUS Phase III study enrolled 385 participants aged 12 years and older across multiple international sites, comparing a 400 mg daily dose of etavopivat with placebo. Results showed a 27% relative reduction in VOC incidence and a median time to first crisis of 38.4 weeks versus 20.9 weeks for placebo, indicating a substantial delay in disease‑driven events. Moreover, nearly half of the treated cohort (48.7%) achieved a hemoglobin increase exceeding 1 g/dL, a clinically meaningful improvement that could translate into better oxygen delivery and reduced organ damage. These outcomes satisfy both co‑primary endpoints, underscoring the drug’s efficacy and safety profile.

Looking ahead, Novo Nordisk aims to submit a regulatory dossier in the second half of 2026, targeting approval in the United States and Europe. If cleared, etavopivat would be the first oral, disease‑modifying therapy for SCD, positioning Novo Nordisk at the forefront of a market projected to exceed $2 billion globally. The company’s move also signals a broader strategic push into hematology, complementing its existing diabetes portfolio and potentially reshaping treatment algorithms for a condition that has long lacked convenient, effective oral options.